Ixekizumab for stubborn guttate psoriasis
Treatments studied
Part of Skin clinical trials.
This study tests a medication called ixekizumab (given as a shot) to see if it works for people with a stubborn form of guttate psoriasis that hasn't improved with standard treatments. It may help reduce your psoriasis spots and improve your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old, of any gender.
- You have a type of psoriasis called guttate (small, drop-like spots).
- You have tried standard treatments (like creams, antibiotics, or light therapy) for at least 4 weeks but still have symptoms.
- Your psoriasis is at least moderately active (PASI score 3+ or DLQI 6+).
- You have never used a biologic drug (like an injection or infusion) for psoriasis before.
- You do not have any active serious infections (like TB, HIV, or hepatitis), other major skin diseases, or other psoriasis types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This trial compares ixekizumab and secukinumab to see which works better for people over 70 with plaque psoriasis. It aims to find a safer and more effective treatment for older adults.
This study looks at how well xeligekimab works for people with moderate to severe plaque psoriasis in everyday medical practice. It may help you if you are about to start this treatment for the first time.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
Hear when a new Guttate Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.